A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT05533775. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Study identification
- NCT ID
- NCT05533775
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 65 participants
Conditions and interventions
Conditions
Interventions
- Carboplatin Drug
- Etoposide Drug
- Glofitamab Drug
- Ifosfamide Drug
- Obinutuzumab Drug
- Rituximab Drug
- Tocilizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 6 Months to 30 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 15, 2022
- Primary completion
- Nov 29, 2029
- Completion
- Nov 29, 2032
- Last update posted
- May 3, 2026
2022 – 2032
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital of Alabama | Birmingham | Alabama | 35233 | Recruiting |
| UCSF Benioff Children's Hospital Oakland | Oakland | California | 94609 | Recruiting |
| Kaiser Permanente Oakland Medical Center | Oakland | California | 94611 | Recruiting |
| Kaiser Permanente - Roseville | Roseville | California | 95661 | Recruiting |
| Kaiser Permanente - Santa Clara | Santa Clara | California | 95051 | Recruiting |
| Johns Hopkins University | Baltimore | Maryland | 21231 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Childrens Mercy Hosp & Clinics | Kansas City | Missouri | 64108 | Recruiting |
| MSKCC | New York | New York | 10065 | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05533775, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 3, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05533775 live on ClinicalTrials.gov.